HomeNewsBusinessCompaniesCOVID-19 impact | Early planning helped us to counter lockdown woes: Sumit Rai, Edelweiss Tokio Life CEO

COVID-19 impact | Early planning helped us to counter lockdown woes: Sumit Rai, Edelweiss Tokio Life CEO

IRDAI data showed that Edelweiss Tokio Life saw a 47.5 percent year-on-year growth in first year premium in April 2020 at Rs 16.46 crore.

May 21, 2020 / 17:54 IST
Story continues below Advertisement

The life insurance industry has been reeling under the impact of a COVID-19-induced slowdown since March 2020 after a nation-wide lockdown was announced to contain the spread of the deadly virus.

However, a handful of companies managed a growth in new premium collection. Edelweiss Tokio Life Insurance is one such company.

Story continues below Advertisement

In an interaction with Moneycontrol, Sumit Rai, MD & CEO, Edelweiss Tokio Life Insurance, said the company started preparing for the lockdown much earlier and hence were able to manage the process better.

Track this blog for latest updates on the coronavirus outbreak

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show